Reading Time: 4 minutes

VICTORIA, British Columbia–(BUSINESS WIRE)–In recognition of Lupus Awareness Month and World Lupus Day, Aurinia
Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (the “Company”) a late
clinical-stage biopharmaceutical company with ongoing research in lupus
nephritis (“LN”), today recognized World Lupus Day and Lupus Awareness
Month with the launch of awareness and educational initiatives to
support people with LN and Systemic Lupus Erythematosus (“SLE”):

  • Today in collaboration with Aurinia, MyLupusTeam, a social
    network and support community for those living with lupus, launched
    the Lupus Nephritis Resource Center. The resource center aims to
    improve LN education and awareness by providing helpful resources and
    information about the signs and symptoms of LN and the importance of
    early diagnosis. To learn more and access these useful resources,
    visit the Lupus
    Nephritis Resource Center
    .
  • ALL
    IN™
    , Aurinia’s educational program and support community for
    people living with LN, has initiated a new campaign called “Send a
    Message to Your Kidneys.” Aurinia invites members of the LN community
    throughout the month of May to submit positive and encouraging
    messages to their kidneys as a source of strength and inspiration for
    those living with LN. Visit www.ALLINforLN.com/kidneymessage
    to submit a message or to view the inspiring messages from others in
    the community.
  • Aurinia has collaborated with national and regional advocacy groups to
    create a Lupus Awareness Month calendar on its corporate website that
    provides access to helpful tips, resources, and activities for people
    with LN and lupus. Access the calendar here: www.auriniapharma.com/calendar.
  • Are you interested in getting involved? Visit, share, or like the
    useful resources regarding LN and SLE that Aurinia posts from our
    handle @AuriniaPharma on Twitter
    and Facebook.

“Up to 50% of people living with lupus may develop lupus nephritis
during their journey, so it’s important that we empower them to better
discuss risk factors, symptoms and testing with their doctors,” said
Eric Peacock, Co-Founder and CEO of MyHealthTeams. “Members of
MyLupusTeam, who are experiencing symptoms of LN, want information that
will help them better understand the condition, and they value the
connection with others facing similar challenges.”

“SLE is a chronic disease with a variable course. It is characterized by
immune cells causing inflammation in otherwise healthy organs,” said
General Manager Americas and Global Commercial Assessment, Brad
Dickerson. “One of the most serious complications of SLE is lupus
nephritis, inflammation of the kidneys, which can lead to permanent
kidney damage and potentially end-stage renal disease (ESRD)”, stated
Dickerson. “As a company with a deep history in researching LN, Aurinia
is committed to continuing to raise awareness and education around this
condition.”

To learn more about LN, visit ALL IN at www.allinforlupusnephritis.com.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is a late clinical-stage biopharmaceutical
company focused on developing and commercializing therapies to treat
targeted patient populations that are impacted by serious diseases with
a high unmet medical need. The company is currently developing an
investigational drug for the treatment of lupus nephritis and focal
segmental glomerulosclerosis. Additionally, the Company is advancing
voclosporin ophthalmic solution (VOS) for the treatment of dry eye
syndrome (DES). The company is headquartered in Victoria, British
Columbia and focuses its development efforts globally. For further
information, see our website at www.auriniapharma.com.

About Lupus Nephritis (“LN”)

LN is an inflammation of the kidney caused by Systemic Lupus
Erythematosus (“SLE”) and represents a serious progression of SLE. SLE
is a chronic, complex and often disabling disorder. The disease is
highly heterogeneous, affecting a wide range of organs and tissue
systems. Unlike SLE, LN has straightforward disease outcomes (measuring
proteinuria) where an early response correlates with long-term outcomes.
In patients with LN, renal damage results in proteinuria and/or
hematuria and a decrease in renal function as evidenced by reduced
estimated glomerular filtration rate (“eGFR”), and increased serum
creatinine levels. LN is debilitating and costly and if poorly
controlled, LN can lead to permanent and irreversible tissue damage
within the kidney, resulting in end-stage renal disease (“ESRD”), thus
making LN a serious and potentially life-threatening condition.

About MyLupusTeam

MyLupusTeam is social network and support community for people living
with lupus. It is one of MyHealthTeam’s 32 and growing communities with
more than 140,000 members. MyHealthTeams creates social networks for
communities of people facing chronic conditions. MyHealthTeams believes
that if you are diagnosed with a chronic condition, it should be easy to
find and connect with others going through the same thing.

Forward-Looking Statements

Certain of the statements made in this presentation may constitute
forward-looking information within the meaning of applicable Canadian
securities law and forward-looking statements within the meaning of
applicable U.S. securities law.

When used in these materials, the words “anticipate”, “will”, “believe”,
“estimate”, “expect”, “intend”, “target”, “plan”, “goals”, “objectives”,
“may” and other similar words and expressions, identify forward-looking
statements or information.

Forward-looking information by their nature are based on assumptions and
involve known and unknown risks, uncertainties and other factors which
may cause the actual results, performance or achievements of Aurinia to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking information.
Should one or more of these risks and uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those described in forward-looking statements or
information. Such risks, uncertainties and other factors include, among
others, the following: the market for the LN business may not be as
estimated; and competitors may arise with similar products.

Although we have attempted to identify factors that would cause actual
actions, events or results to differ materially from those described in
forward-looking statements and information, there may be other factors
that cause actual results, performances, achievements or events to not
be as anticipated, estimated or intended. Also, many of the factors are
beyond our control. There can be no assurance that forward-looking
statements or information will prove to be accurate, as actual results
and future events could differ materially from those anticipated in such
statements. Accordingly, you should not place undue reliance on
forward-looking statements or information.

Except as required by law, Aurinia will not update forward-looking
information. All forward-looking information contained in this
presentation is qualified by this cautionary statement. Additional
information related to Aurinia, including a detailed list of the risks
and uncertainties affecting Aurinia and its business can be found in
Aurinia’s most recent Annual Information Form available by accessing the
Canadian Securities Administrators’ System for Electronic Document
Analysis and Retrieval (SEDAR) website at www.sedar.com
or the U.S. Securities and Exchange Commission’s Electronic Document
Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar.

We seek Safe Harbour.

Contacts

Aurinia Pharmaceuticals Inc.
Investor Inquiries:
Glenn
Schulman, PharmD, MPH
Corporate Communications
[email protected]
or
Media
Inquiries:

Christopher Hippolyte
212-364-0458
[email protected]